Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Blood|April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Blood Cancer Journal|March 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutationsWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
Blood|February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitorsDyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
Plos One|December 30, 2020
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeuticsRichard L Cullum, Lauren M Lucas, Jared I Senfeld, et al.
Leukemia|December 22, 2018
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AMLDyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Pageof 4